Real-World Effectiveness and Safety of Dotinurad in Chinese Patients with Gout: A Comparative Analysis

Guanqun Yi, Xuechan Huang, Yukai Huang, Zhixiang Huang, Shaoling Zheng, Zhengping Huang, Weiming Deng, Chun Zheng, Tianwang Li · 2026

Read Real-World Effectiveness and Safety of Dotinurad in Chinese Patients with Gout: A Comparative Analysis by Guanqun Yi, Xuechan Huang, Yukai Huang, Zhixiang Huang, Shaoling Zheng, Zhengping Huang, Weiming Deng, Chun Zheng, Tianwang Li (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13570847.txt.

Description

Yi and colleagues published a 2026 study on a newer gout drug used in China. Gout flares when uric acid builds up and crystals form in joints. Dotinurad lowers uric acid by blocking its reuptake in the kidneys. The team compared it with febuxostat, a standard option, in 70 patients.

After one month, 60 percent on dotinurad hit the main uric acid target. The febuxostat group reached that target in about 46 percent of cases. For the stricter target, dotinurad led by a wider margin still. Blood uric acid ended clearly lower in the dotinurad group at week four. Liver and kidney safety checks showed no added risk with dotinurad. Longer follow-up will show whether the early edge holds over time.

Catalog record

CREATORGuanqun Yi, Xuechan Huang, Yukai Huang, Zhixiang Huang, Shaoling Zheng, Zhengping Huang, Weiming Deng, Chun Zheng, Tianwang Li
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE32 KB
LICENSEhttps://creativecommons.org/licenses/by/4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/article/MED/PMC13570847

Browse the full library · About the Tower of Babel